实用医学杂志 ›› 2025, Vol. 41 ›› Issue (9): 1407-1412.doi: 10.3969/j.issn.1006-5725.2025.09.020

• 医学检查与临床诊断 • 上一篇    

B7族同源体3、过氧化物酶1、硫氧还蛋白在溃疡性结肠炎及其相关性结直肠癌患者血清和组织中的表达及意义

吴娜,张泽天,王锐   

  1. 河北北方学院附属第一医院消化内科 (河北 张家口 075000 )
  • 收稿日期:2025-01-17 出版日期:2025-05-10 发布日期:2025-05-20
  • 基金资助:
    河北省卫生健康委科研基金项目(20210824)

The expression and clinical significance of B7⁃H3, PRDX1, and TRX in the serum and tissues of patients with ulcerative colitis and its related colorectal cancer

Na WU,Zetian ZHANG,Rui WANG   

  1. Department of Gastroenterology,the First Affiliated Hospital of Hebei North University,Zhangjiakou 075000,Hebei,China
  • Received:2025-01-17 Online:2025-05-10 Published:2025-05-20

摘要:

目的 探究B7族同源体3(B7-H3)、过氧化物酶1(PRDX1)、硫氧还蛋白(TRX)在溃疡性结肠炎(UC)及其相关性结直肠癌(UC-CRC)患者血清和组织中的表达及临床意义。 方法 选取2019年1月至2023年12月接受检查的UC患者108例作为UC组,选择同期接受检查的UC-CRC患者108例作为UC-CRC组,另选择108例同期结肠镜检查无异常者作为对照组。血清B7-H3、PRDX1、TRX表达水平采用酶联免疫吸附法(ELISA)测定;UC-CRC及UC患者组织中B7-H3、PRDX1、TRX的表达采用免疫组化法检测;血清B7-H3、PRDX1、TRX水平对UC-CRC患者的诊断价值绘制受试者工作特征(ROC)曲线分析。 结果 与对照组相比,UC组、UC-CRC组血清B7-H3、PRDX1、TRX表达水平均依次显著升高(P < 0.05)。与静息期UC组相比,发病期UC组血清B7-H3、PRDX1、TRX表达水平升高(P < 0.05)。与UC组相比,UC-CRC组组织中B7-H3、PRDX1、TRX阳性表达率均显著升高(P < 0.05)。血清B7-H3、PRDX1、TRX三者联合诊断UC-CRC的AUC最高,优于血清B7-H3、PRDX1、TRX各自单独诊断(Z三者联合-B7-H3 = 2.829、P = 0.005,Z三者联合-PRDX1 = 2.544、P = 0.011,Z三者联合-TRX = 3.673、P < 0.001)。 结论 B7-H3、PRDX1、TRX在UC-CRC患者血清和组织中均呈现高表达,三者联合可以用于诊断UC-CRC发生。

关键词: B7族同源体3, 过氧化物酶1, 硫氧还蛋白, 溃疡性结肠炎, 结直肠癌

Abstract:

Objective To investigate the expression levels and clinical significance of B7 homolog 3(B7-H3), peroxiredoxin 1 (PRDX1), and thioredoxin (TRX) in the serum and tissues of patients with ulcerative colitis (UC) and UC-associated colorectal cancer (UC-CRC). Methods A total of 108 patients with UC who underwent examination in our hospital between January 2019 and December 2023 were enrolled in the UC group. Additionally, 108 patients with UC-CRC who were examined in our hospital were included in the UC-CRC group. Furthermore, 108 individuals without any abnormalities detected during colonoscopy were recruited as the control group. The serum levels of B7-H3, PRDX1, and TRX were quantified using enzyme-linked immunosorbent assay (ELISA). The expression of B7-H3, PRDX1, and TRX in tissues from UC-CRC and UC patients was assessed by immunohistochemistry. The diagnostic performance of serum B7-H3, PRDX1, and TRX levels for UC-CRC was evaluated by constructing receiver operating characteristic (ROC) curves. Results Compared with the control group, the serum expression levels of B7-H3, PRDX1, and TRX in both the UC group and the UC-CRC group were significantly elevated in sequence (P < 0.05). In comparison to the resting UC group, the serum expression levels of B7-H3, PRDX1, and TRX in the episodic UC group also increased significantly (P < 0.05). Furthermore, compared with UC patients, the positive expression rates of B7-H3, PRDX1, and TRX in the tissues of UC-CRC patients were markedly higher (P < 0.05). The combination of serum B7-H3, PRDX1, and TRX demonstrated the highest AUC for diagnosing UC-CRC patients, outperforming the individual diagnostic performance of each biomarker (Zcombination-B7-H3 = 2.829, P = 0.005, Zcombination-PRDX1 = 2.544, P = 0.011, Zcombination-TRX = 3.673, P < 0.001). Conclusion B7-H3, PRDX1, and TRX are significantly overexpressed in both the serum and tissues of UC-CRC patients, and their combined evaluation holds potential as a diagnostic tool for detecting the development of UC-CRC.

Key words: B7 homolog 3, peroxiredoxin 1, thioredoxin, ulcerative colitis, colorectal cancer

中图分类号: